Category
81 articles — page 2 of 7
May 14, 2026
The three main topical approaches to vitiligo — JAK inhibitor (Opzelura), calcineurin inhibitor (tacrolimus), and corticosteroids — each have different mechanisms, evidence levels, side effects, and appropriate uses. Here is the complete comparison.
May 14, 2026
Polypodium leucotomos is an oral fern extract with antioxidant and photoprotective properties. The evidence base for its use as a phototherapy adjunct in vitiligo is modest but real — here is what the trials actually show.
May 14, 2026
Pseudocatalase cream (PC-KUS) is frequently asked about in vitiligo communities. The evidence is weak, the mechanism is contested, and the product is not widely available. Here is the honest assessment.
May 14, 2026
PUVA — psoralen plus UVA — was the standard phototherapy for vitiligo for decades before narrowband UVB became dominant. It still has a role in specific situations. Here is how it works and how it compares to NbUVB.
May 14, 2026
Ruxolitinib cream (Opzelura) and tacrolimus are the two most-discussed topical treatments for vitiligo. They work by different mechanisms, have different evidence bases, and suit different patients. Here is the direct head-to-head comparison.
May 14, 2026
Tofacitinib is an oral JAK inhibitor used off-label for vitiligo, with a growing body of case series and small trial evidence. It predates ruxolitinib and baricitinib as a JAK inhibitor in clinical use, but carries a more complex safety profile.
May 14, 2026
Vitiligo and alopecia areata co-occur more frequently than chance would predict, share autoimmune mechanisms, and — critically — both respond to JAK inhibitors. Understanding the overlap has real treatment implications.
May 14, 2026
Atopic dermatitis (eczema) co-occurs with vitiligo at elevated rates, and both conditions respond to topical calcineurin inhibitors. Here is how to manage the two together without treatments conflicting.
May 14, 2026
Co-occurrence of vitiligo and psoriasis is documented and more common than chance predicts. JAK inhibitors have evidence for both conditions, creating a treatment opportunity for patients with the overlap.
May 14, 2026
Perioral vitiligo — patches around the mouth — is highly visible, emotionally difficult, and presents specific treatment challenges distinct from lip vitiligo or general facial vitiligo. Here is what works and what to expect.
May 14, 2026
Clinical trials offer access to cutting-edge vitiligo treatments before they are widely approved, at no drug cost. Here is how to find active trials, assess eligibility, and understand what participation actually involves.
May 14, 2026
Vitiligo affects people of all skin tones, but the experience on darker skin is meaningfully different — higher contrast, greater stigma, and specific treatment considerations. Here is what the research and patient experience actually show.
